LDL-C Monitoring Frequency After the Diagnosis of Diabetes or Atherosclerotic Cardiovascular Disease

被引：0
|
作者：
Cohen, Sarah S.
Chamberlain, Alanna M.
Killian, Jill M.
Monda, Keri L.
Weston, Susan A.
Okerson, Ted
机构：
来源：
CIRCULATION | 2017年 / 136卷
关键词：
Statins; LDL; Epidemiology; Diabetes; Mellitus; Cardiovascular disease;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
15727
引用
收藏
页数：2
相关论文
共 50 条
  • [21] LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature
    Ravnskov, Uffe
    de Lorgeril, Michel
    Diamond, David M.
    Hama, Rokuro
    Hamazaki, Tomohito
    Hammarskjold, Bjorn
    Hynes, Niamh
    Kendrick, Malcolm
    Langsjoen, Peter H.
    Mascitelli, Luca
    McCully, Kilmer S.
    Okuyama, Harumi
    Rosch, Paul J.
    Schersten, Tore
    Sultan, Sherif
    Sundberg, Ralf
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (10) : 959 - 970
  • [22] Peripheral arterial Disease LDL-C and cardiovascular Risk significantly lowering with Evolocumab
    Unger-Hunt, Lydia
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2018, 11 (02): : 68 - 70
  • [23] ACHIEVEMENT OF LDL-C TARGETS IN CHINESE PATIENTS WITH VERY HIGH RISK ATHEROSCLEROTIC CARDIOVASCULAR DISEASE RECEIVING INTENSIVE LIPID LOWERING THERAPY
    Cheng, Y.
    Dong, S.
    Shen, P.
    Sun, Y.
    Lin, H.
    Zhai, S.
    VALUE IN HEALTH, 2022, 25 (01) : S24 - S24
  • [24] ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease
    Sniderman, Allan D.
    CLINICAL CHEMISTRY, 2021, 67 (11) : 1440 - 1442
  • [25] Knowledge of HbA1c and LDL-C treatment goals, subjective level of disease-related information and information needs in patients with atherosclerotic cardiovascular disease
    Brockmeyer, Maximilian
    Wies, Emilia
    Joerges, Jamuna
    Sommer, Jana
    Borgmann, Sandra Olivia
    Chernyak, Nadja
    Lin, Yingfeng
    Parco, Claudio
    Schulze, Volker
    Heinen, Yvonne
    Kelm, Malte
    Icks, Andrea
    Perings, Stefan
    Wolff, Georg
    CLINICAL CARDIOLOGY, 2023, 46 (02) : 223 - 231
  • [26] IMPORTANCE OF BASELINE LDL-C IN THE ASSOCIATION BETWEEN LDL-C LOWERING AND CARDIOVASCULAR RISK: A META-REGRESSION ANALYSIS
    Hawe, E.
    Meleth, S.
    Wolowacz, S.
    Bilitou, A.
    ATHEROSCLEROSIS, 2022, 355 : E266 - E267
  • [27] Serious flaws in targeting LDL-C reduction in the management of cardiovascular disease in familial hypercholesterolemia
    Ravnskov, Uffe
    de Lorgeril, Michel
    Kendrick, Malcolm
    Diamond, David M.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (03) : 405 - 406
  • [28] A LASSO-derived model for the prediction of nonattainment of target LDL-C reduction with PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease
    Duan, Xiaochun
    Zhang, Mengdi
    Sun, Xiaodong
    Lin, Yang
    Peng, Wenxing
    LIPIDS IN HEALTH AND DISEASE, 2025, 24 (01)
  • [29] The correlation between lipoprotein(a) and coronary atherosclerotic lesion is stronger than LDL-C, when LDL-C is less than 104 mg/dL
    Chuang Li
    Qiwen Chen
    Mei Zhang
    Yin Liu
    Yushun Chu
    Fanpeng Meng
    Jianyu Wang
    Jie Tang
    Jian Luo
    Xiulong Niu
    Maoti Wei
    BMC Cardiovascular Disorders, 21
  • [30] Effects of Serum LDL-C, CysC, and D-D in Patients with Coronary Atherosclerotic Heart Disease
    Shen, Chaofeng
    Wang, Jing
    Tu, Sijia
    COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE, 2022, 2022
12345